Modality
Peptide
MOA
PARPi
Target
TNFα
Pathway
RAS/MAPK
AMLAtopic Derm
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
~Jan 2019
→ ~Apr 2020
NDA/BLA
Jul 2020
→ Feb 2029
NDA/BLACurrent
NCT08909471
235 pts·AML
2020-07→2029-02·Active
NCT05216372
1,321 pts·AML
2024-12→2028-06·Completed
1,556 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-06-182.2y awayPh3 Readout· AML
2029-02-162.9y awayPh3 Readout· AML
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
NDA/BLA
Active
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2028-06-18 · 2.2y away
AML
Ph3 Readout
2029-02-16 · 2.9y away
AML
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| Cevifotisoran | Neurocrine | Approved | CD47 |